Inhibition of cyclooxygenase-1-dependent signaling between platelets and HT29 colon cancer cells by aspirin prevents upregulation of Twist-1 and repression of E-cadherin

A. Bruno¹, M. Dovizio², S. Alberti², A. Sacco², S. Schiavone², A. Sgambato³, T.J. Maier⁴, D. Steinhilber⁴, P. Patrignani²

Twist-1 plays a key role in epithelial-mesenchymal transition (EMT) and metastasis by repressing E-cadherin-mediated cell-cell adhesion and inducing mesenchymal markers and cell motility (Kalluri et al., 2009). Prostaglandin(PG)E₂ signaling mediates EMT and cell migration/invasion (Dovizio et al. 2013). We aimed to address the hypothesis that:(i)tumor cell/platelet cross-talk induces PGE2 release which may play a role in Twist-1 mRNA up-regulation and Ecadherin mRNA down-regulation, and (ii) selective inhibition of platelet-dependent PGE₂ by aspirin may affect these changes in gene expression. Co-cultures with human colon carcinoma cells (HT29) and platelets were performed for 20 h. In some experiments, platelets were pretreated with aspirin(300 microM), to completely suppress cyclooxygenase(COX)-1 activity. HT29 expressed PGE2 receptors(i.e., EP1, EP2 and EP4, but not EP3 and thromboxane A2 receptor). Exogenous PGE₂(1.5 ng/ml) added to HT29 cells induced a significant increase of Twist-1 mRNA and down-regulation of E-cadherin mRNA. In platelet-HT29 co-cultures, PGE₂ release(1.3±0.1ng/ml) was higher than in platelets and HT29 cultured alone. In co-cultures, HT29 mRNA levels of Twist-1 were significantly increased by 4-fold while E-cadherin mRNA levels were significantly reduced by 42% versus HT29 cultured alone. Aspirin pre-treatment of platelets prevented the changes of Twist-1 and E-cadherin mRNA levels in HT29 cells and they were rescued by the addition of PGE₂. In conclusion, selective inhibition of platelet COX-1-dependent PGE2 by aspirin prevented enhanced expression of Twist-1 and downregulation of E-cadherin caused in HT29 by platelet interaction. These results open the way to study in animal models and patients the role of this mechanism in the anti-metastatic effect of low-dose aspirin detected in clinical trials.

References

Kalluri R, Weinberg RA (2009) J Clin Invest. 119: 1420-8.

Dovizio M, Maier TJ, Alberti S, Di Francesco L, Marcantoni E, Munch G, John CM, Suess B, Sgambato A, Steinhilber D, Patrignani P (2013). *Mol Pharmacol*. [Epub ahead of print].

¹Dept. of Medicine and Aging, 'G. d'Annunzio' University of Chieti, Italy

²Dept. of Neuroscience and Imaging, 'G. d'Annunzio' University of Chieti, Italy,

³Institute of General Pathology, Catholic University, Rome, Italy,

⁴Institutes of Pharmaceutical Chemistry, Frankfurt University, Frankfurt, Germany